Term
| synthetic B lactam antibacterials |
|
Definition
|
|
Term
| UTIs (enterobacter, proteus, pseudomonas), respiratory tract infectiosn (streptococcus pneumoniae and klebsiella pneumonaie) and various noscomial infections (serratia and acinetobacter) |
|
Definition
| Imipenem/cilastatin (Primaxin) |
|
|
Term
| similar to imipenem in activity but has greater activity vs gram negative aerobes and less vs gram positive |
|
Definition
|
|
Term
| similar to meropenem in activity and exhibits superior activity against Pseudomonas aeruginosa over other carbapenems |
|
Definition
|
|
Term
| similar in activity to imipenem in activity, but is INACTIVE vs Pseudomonas and Acinetobacter |
|
Definition
|
|
Term
| useful for empiric therapy since they are active against a wide range of organisms and are resistant to most B lactamases |
|
Definition
|
|
Term
| administered either IV or IM and well distributed |
|
Definition
|
|
Term
| metabolized by a renal dehydropeptidase to a potentially nephrotoxic inactive metabolite |
|
Definition
|
|
Term
| dehydropeptidase inhibitor therefore formulation with imipenem inhibits formulation of toxic metabolite |
|
Definition
|
|
Term
| increases urinary concentration of imipenem and permits it to be effective in treatment of UTIs |
|
Definition
|
|
Term
not metabolized by renal dehydropeptidase
therefore do not needt o be given with cilastatin |
|
Definition
| meropenem, doripenem, ertapenem |
|
|
Term
| high concentrations of this may induce seizures during renal failure |
|
Definition
|
|
Term
| may induce nausea, vomiting, diarrhea, and skin rashes |
|
Definition
|
|
Term
| only monobactam on market |
|
Definition
| aztrenonam (azactam, Cayston) |
|
|
Term
| also inhibits bacterial cell wall synthesisa and exhibits resistance to inactivation by B lactamases (not carbapenem) |
|
Definition
|
|
Term
| ONLY USEFUL against aerobic gram negative bacilli, particuarly Pseudomonas and Serratia |
|
Definition
|
|
Term
| Only active vs. G- bacteria particuarly Pseudomonas and Serratia but also: Proteus mirabilis, E. Coli, Klebsiella pneumo, Neisseria, Enterobacter, Haemophilus influenzae, Moraxella catarrhalis, Pasteurella, Citrobacter |
|
Definition
|
|
Term
| clinically employed in the treatment of urinary tract and respiratory tract infections |
|
Definition
|
|
Term
| POrimary indications include treatment of UTIs (Pseudomonas, E. Coli, Proteus). Due to Klebseilla infections and nocosimal infections (serratia) |
|
Definition
|
|
Term
| Improvement of respiratory symptoms in cystic fibrosis pts (7 years and older) w/ Pseudomonas aeruginosa |
|
Definition
|
|
Term
| Also indicated for treatment of bacteremias, skin and sot tissue infections, and intra abdominal infections |
|
Definition
|
|
Term
|
Definition
|
|
Term
| inhalation form of aztreonam is called |
|
Definition
|
|
Term
|
Definition
|
|
Term
| not cross allergenic with other beta lactams |
|
Definition
|
|
Term
| Associated w/ skin rashes |
|
Definition
|
|
Term
| Gram positive cocci, gram negative rods, anaerobes. Wide spectrum but the significant side effects limit use to life threatening infections or after otehr drugs have failed |
|
Definition
|
|
Term
| broadest antibacterial activity of any antibiotic known to man |
|
Definition
|
|
Term
| MRSA, some speudomonas species (not aeruginosa, which is susceptible), and bacteria w/o peptidoglycan walls are still susceptible to our super broad |
|
Definition
|
|
